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The eﬀect of pregnancy on simultaneous pancreas-kidney transplant recipients has previously been described, but experience is
limited. We describe the case of a thirty-ﬁve-year-old female who previously underwent simultaneous pancreas-kidney transplant
for type 1 diabetes mellitus-complicated nephropathy. An integrated multidisciplinary team including the transplant team,
nephrologist, endocrinologist, and obstetrician closely followed progress during pregnancy. Blood glucose levels and HbA1c
remained within normal limits, and she did not require insulin treatment at any point. She experienced deterioration in renal
indicesandunderwentanuncomplicated,electiveCaesareansectionatthirty-weekgestation.Shedeliveredamaleinfantof1.18kg,
appropriate for gestational age, who had hypothermia and respiratory distress, which required intubation and ventilation and an
eleven-week stay in the special care baby unit. At eighteen-month followup the infant shows normal development, and there has
been no deterioration in either grafts’ function.
1.Introduction
The ﬁrst pregnancy in the recipient of a simultaneous
pancreas-kidneytransplant(SPKT)wasreportedin1986[1].
Increasingnumbersofwomenofchildbearingageworldwide
are undergoing transplantation, including SPKT. The major-
ity of data from pregnancy in transplant recipients comes
fromtherenaltransplantpopulation.InSPKTrecipients,the
presence of two organs within the pelvis may pose additional
risks. There are risks to both mother and newborn [2, 3]
including miscarriage, preterm birth, foetal malformations
[4], deterioration in maternal renal function, pre-eclampsia,
infection, and pancreas-graft pancreatitis induced by normal
delivery [5].
Diabetes is the leading cause of renal failure in adult
patients, and in select cases, pancreas transplantation has
beenperformedsincethemid-1980s[6].Pancreastransplan-
tation has a beneﬁcial eﬀect on nephropathy [7], autonomic
neuropathy [8], and peripheral neuropathy [9] which may
lead to improved quality of life [10]. Renal impairment,
such as that occurring secondary to diabetic nephropathy,
may result in gonadal insuﬃciency with resultant infertility.
SPKT can restore fertility in patients with diabetes and end-
stage renal disease [11], and as such, successful pregnancy
outcomes can be achieved [12, 13].
Compared to kidney transplant recipients, SPKT recip-
ients have similar rates of spontaneous miscarriage and
therapeutic abortion, but higher rates of preterm delivery,
low birth weight, hypertension, infection, pre-eclampsia,
acute rejection, and graft loss in later years [14]. Risks
are reduced if pregnancy is planned and if the graft is
functional at least one-year after transplantation without
evidence of rejection; with normal blood pressure and stable
immunosuppression doses [15]. We present a case of a
planned pregnancy in such a patient.
2.CaseDescription
A thirty-ﬁve-year-old female with a complex medical history
presentedatsixweeksofgestation.Shehadahistoryoftype12 Case Reports in Obstetrics and Gynecology
diabetes mellitus diagnosed at the age of ten, complicated
by retinopathy, bilateral cataract surgery, and nephropathy
(which required renal replacement therapy). Six years previ-
ously, she underwent SPKT with the pancreas allograft sited
in the right iliac fossa and the renal allograft in the left
iliac fossa. The donor was CMV positive, and our patient
was negative. Human leucocyte antigen (HLA) mismatching
showed no HLA-A mismatch, one HLA-B mismatch, and
two HLA-DR mismatches. Induction immunosuppressive
therapy for transplant included antithymocyte globulin
and in the postoperative state tacrolimus, mycophenolate
mofetil, and prednisolone were prescribed in addition to
standard antiviral (ganciclovir) and antifungal (ﬂuconazole)
therapies. Recovery from transplant was uneventful, and
she soon achieved normoglycaemia and good renal allograft
function, with serum creatinine of 92mmol/L on the eighth
postoperative day.
Due to the high-risk nature of these cases, pregnancy was
planned, and during preconceptual counseling, treatments
were optimized. Due to the risk of foetal teratogenicity,
mycophenolatemofetilwaschangedtoazathioprine.Further
immunosuppressive doses were stable prior to pregnancy.
There was evidence of good function of both renal and
pancreas allografts with serum creatinine of 146mmol/L
with fasting blood glucose of 4.1mmol/L. As she had a
history of polycystic ovarian syndrome with prolonged
amenorrhoea, she attended fertility services and required
hormonal support to achieve pregnancy. Recombinant FSH
was used to stimulate ovulation, and singleton pregnancy
wasachievedonthesixthcycleoftreatment.Progesteronegel
(8%) was used until week fourteen of gestation. Throughout
the pregnancy, the transplant team as well as her nephrolo-
gist, endocrinologist, and obstetrician with a special interest
in high-risk pregnancy closely followed her progress.
Despite normotensive prepregnancy, at nine weeks of
gestation, she had high systolic and diastolic blood pressure
readings on home monitoring, conﬁrmed on clinical assess-
ment. She was diagnosed with pregnancy-induced hyperten-
sion and commenced labetalol therapy, which was uptitrated
throughoutpregnancy.Vaginalbleedingoccurredtransiently
at eleven weeks of gestation, which resolved spontaneously.
Multiple scans for fetal well-being were performed, and
no fetal anomalies were noted including normal amniotic
ﬂuid and placental structure and function. Ophthalmology
reviews during pregnancy noted no deterioration in diabetic
retinopathy. Tacrolimus doses were adjusted based on close
monitoring of trough levels throughout the pregnancy,
whilst prednisolone and azathioprine doses remained stable.
Tacrolimus levels were stable throughout pregnancy and
within the accepted target range of 6–10. Blood glucose
monitoring, fasting blood glucose, and serial glycosylated
haemoglobin (HbA1c) levels were in the normal range
throughout pregnancy. Insulin treatment was not required
at any stage before, during, or after pregnancy.
Serum creatinine was stable prior to pregnancy but
steadily increased throughout the pregnancy. She experi-
enced deterioration in renal function at twenty-six weeks of
gestation and was admitted for monitoring. Intramuscular
betamethasone to enhance foetal lung maturity was admin-
istered during this admission. Renal indices were transiently
stabilized, but due to further deterioration of delivery was
planned for thirty weeks and three days of gestation. She
underwent elective Caesarian section (Pfannenstiel incision)
under epidural anaesthesia, performed by her local obstetri-
cian with assistance from the original transplant surgeon to
monitor both grafts. The procedure was uncomplicated, and
no deterioration in graft function was observed.
She delivered a male infant who had APGAR scores of
seven and nine at ﬁve and ten minutes, respectively. Birth
weightwas1.18kg,whichwasappropriateforgestationalage
based on foetal birth weight centile. He was hypothermic
and had evidence of respiratory distress, which required
intubation and ventilation, and he was admitted to the
special care baby unit, where he remained for eleven weeks.
Following discharge to home, the infant experienced no
further complications. Following delivery, our patient expe-
rienced progression of hypertension transiently and required
the addition of amlodipine for three days. Following this,
she developed labile blood pressure, and all antihypertensive
agents were discontinued. At eighteen-month followup, she
had no evidence of hypertension.
3. Discussion
Multiple pregnancies have been reported in SPKT recip-
ients, including those who required assisted reproductive
technology [16], such as in our case. Overall, SPKTs are
felt to be able to provide suﬃcient metabolic support
throughout a pregnancy [17]. These pregnancies are felt to
be of high risk and require close monitoring with integrated
multidisciplinary care from healthcare professionals [18,
19] including nephrology, obstetrics, endocrinology, and
paediatrics[20].Astheriskofgraftlossoradversepregnancy
outcome is highest in the ﬁrst year after transplantation [15],
patients should be counseled on the risks of graft loss, mater-
nal morbidity and maternal mortality. The importance of
contraception, following transplantation, should be stressed
in order to facilitate planning of pregnancy [11].
A balance between the risk of graft rejection and the
potential teratogenic eﬀect of immunosuppressive medica-
tions must been struck. Importantly, inadequate levels of
immunosuppression may result in acute allograft rejection
[2]. Cyclosporine was traditionally the agent of choice, but
newer agents such as tacrolimus are now frequently used,
as was in our case. Tacrolimus-based regimens continue
to carry a risk of prematurity, preterm delivery, low birth
weight, and IUGR similar to other immunosuppressive
agents [21] but overall are felt safe for use during pregnancy
[22, 23]. Mycophenolate mofetil is absolutely contraindi-
cated during pregnancy due to a high incidence of structural
malformations [24]. It was for this reason that our patient
was transitioned to azathioprine, which has been shown to
be nonteratogenic [25, 26].
As pregnancy may aﬀect the hepatic cytochrome P450
system with resultant ﬂuctuations in serum tacrolimus level
[27], which may result in the increase of tacrolimus require-
mentinpregnancy[28],frequentmonitoringoftroughlevelsCase Reports in Obstetrics and Gynecology 3
was performed during pregnancy with appropriate adjust-
ment of dosage. Tacrolimus toxicity could have contributed
to elevated serum creatinine levels and hypertension [29],
but this was not seen at any stage during this case. In the
postpartum period, drug levels may increase dramatically,
and continued close monitoring is advised. During followup,
tacrolimus requirement rapidly decreased in our case, and
with close monitoring, she did not develop any evidence
of tacrolimus toxicity. Most reported cases of SPKT remain
normoglycaemic during pregnancy, and gestational diabetes
has been previously reported, particularly in those on both
tacrolimus and prednisolone [30]. In this case, pancreatic
function was normal before pregnancy, during pregnancy,
and in the postpartum period. Although anatomically allo-
grafts are not likely to be damaged by foetal descent and
vaginal delivery, the majority of deliveries in SPKT recipients
are by caesarean section [31] .I no u rc a s e ,ac o m b i n e d
decision was made for planned delivery by caesarean section
with an experienced transplant surgeon available in the
event of any complication, as suggested in the international
guidelines [32].
This case highlights the diﬃculties encountered in the
management of pregnancy in SPKT recipients including the
need for planning of pregnancy, ensuring that immunosup-
pression doses are stable, and monitoring graft function and
the importance of planning delivery. Despite multiple issues
encountered in the management of this pregnancy, it was
successful with overall good maternal and foetal outcomes,
despite preterm delivery. In order to achieve successful
pregnancy outcomes, we suggest that an integrated, mul-
tidisciplinary team including endocrinology, nephrology,
obstetrics, and transplant surgeons jointly manages such
cases.
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